225 related articles for article (PubMed ID: 16491071)
1. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
Cheok MH; Evans WE
Nat Rev Cancer; 2006 Feb; 6(2):117-29. PubMed ID: 16491071
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of childhood acute lymphoblastic leukemia.
Brenner TL; Pui CH; Evan WE
Curr Opin Mol Ther; 2001 Dec; 3(6):567-78. PubMed ID: 11804271
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics in acute lymphoblastic leukemia.
Cheok MH; Pottier N; Kager L; Evans WE
Semin Hematol; 2009 Jan; 46(1):39-51. PubMed ID: 19100367
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of acute leukemia.
Ansari M; Krajinovic M
Pharmacogenomics; 2007 Jul; 8(7):817-34. PubMed ID: 18240908
[TBL] [Abstract][Full Text] [Related]
5. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia.
Pui CH; Relling MV; Evans WE
Best Pract Res Clin Haematol; 2002 Dec; 15(4):741-56. PubMed ID: 12617874
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy.
Relling MV; Ramsey LB
Hematology Am Soc Hematol Educ Program; 2013; 2013():126-30. PubMed ID: 24319173
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of acute lymphoblastic leukemia.
Kager L; Evans WE
Curr Opin Hematol; 2006 Jul; 13(4):260-5. PubMed ID: 16755223
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
Davidsen ML; Dalhoff K; Schmiegelow K
J Pediatr Hematol Oncol; 2008 Nov; 30(11):831-49. PubMed ID: 18989161
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic considerations of xenograft mouse models of acute leukemia.
Guihard S; Peyrouze P; Cheok MH
Pharmacogenomics; 2012 Nov; 13(15):1759-72. PubMed ID: 23171339
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia.
Pui CH; Jeha S
Nat Rev Drug Discov; 2007 Feb; 6(2):149-65. PubMed ID: 17268486
[TBL] [Abstract][Full Text] [Related]
12. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.
Kager L
J BUON; 2009 Sep; 14 Suppl 1():S181-6. PubMed ID: 19785064
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.
Aplenc R; Lange B
Br J Haematol; 2004 May; 125(4):421-34. PubMed ID: 15142113
[TBL] [Abstract][Full Text] [Related]
14. Childhood acute lymphoblastic leukaemia--current status and future perspectives.
Pui CH; Campana D; Evans WE
Lancet Oncol; 2001 Oct; 2(10):597-607. PubMed ID: 11902549
[TBL] [Abstract][Full Text] [Related]
15. Building better therapy for children with acute lymphoblastic leukemia.
Carroll WL; Raetz EA
Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
Ansari M; Krajinovic M
Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.
Maxwell RR; Cole PD
Curr Hematol Malig Rep; 2017 Jun; 12(3):176-186. PubMed ID: 28317081
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of acute leukemia.
Cheok MH; Lugthart S; Evans WE
Annu Rev Pharmacol Toxicol; 2006; 46():317-53. PubMed ID: 16402908
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenomics of acute lymphoblastic leukemia].
Ansari M; St-Onge G; Krajinovic M
Med Sci (Paris); 2007 Nov; 23(11):961-7. PubMed ID: 18021708
[TBL] [Abstract][Full Text] [Related]
20. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate.
Niedzielska E; Węcławek-Tompol J; Matkowska-Kocjan A; Chybicka A
Adv Clin Exp Med; 2013; 22(4):579-84. PubMed ID: 23986219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
